Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Asahi Kasei Buys Arthritis Drug

June 23, 2008 | A version of this story appeared in Volume 86, Issue 25

Japanese chemical maker Asahi Kasei has bought the Japanese rights to sell pentosan sodium polysulfate for treating osteoarthritis. Launched in 1947 by the German firm Dr. W. Benend as an anticoagulant, pentosan has since been approved for uses including treatment of the bladder ailment interstitial cystitis. The drug is in Phase I clinical trials in Japan as an arthritis treatment. Asahi will undertake development from Phase II trials onward. If pentosan is approved, Asahi will pay undisclosed sums to a Benend affiliate and ReqMed, a small Japanese firm that promotes drug development.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.